Trade MRTX

Mirati Therapeutics Inc

-

00:00:00

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Read more...

MRTX
Trading Specifications

Digits

3

Point

0.001

Spread

 
floating

Contract Size

1

Volume Min

1

Volume Max

10,000

Volume Step

1

Swap Long (Points)

 
-18.740

Swap Short (Points)

-10.850
Available on
MT5, TV, cTrader
Last update at May 27, 13:01 GMT+3
*Data Source: MT5 Server Prime Account Pricing

1D Change

-0.010%

Why BlackBull Markets?

26k+

Tradable Assets

1:500

Leverage up to

Regulated

Multi-Regulated

24/7

Customer Support

$0

No Minimum Deposit

Margin Calculator

Calculation Results

Current Price

58.64

Required Margin

Converted Currency

Required Margin

Account Base Currency

Profit/Loss Calculator

Calculation Results

PIP Value:

Stop loss in PIPs

Stop loss at :

Take profit in PIPs

Take profit at :

Swaps Calculator

Calculation Results

58.64

|

Join Now